LRRN4 and UPK3B Are Markers of Primary Mesothelial Cells

Background Mesothelioma is a highly malignant tumor that is primarily caused by occupational or environmental exposure to asbestos fibers. Despite worldwide restrictions on asbestos usage, further cases are expected as diagnosis is typically 20–40 years after exposure. Once diagnosed there is a very poor prognosis with a median survival rate of 9 months. Considering this the development of early pre clinical diagnostic markers may help improve clinical outcomes. Methodology Microarray expression arrays on mesothelium and other tissues dissected from mice were used to identify candidate mesothelial lineage markers. Candidates were further tested by qRTPCR and in-situ hybridization across a mouse tissue panel. Two candidate biomarkers with the potential for secretion, uroplakin 3B (UPK3B), and leucine rich repeat neuronal 4 (LRRN4) and one commercialized mesothelioma marker, mesothelin (MSLN) were then chosen for validation across a panel of normal human primary cells, 16 established mesothelioma cell lines, 10 lung cancer lines, and a further set of 8 unrelated cancer cell lines. Conclusions Within the primary cell panel, LRRN4 was only detected in primary mesothelial cells, but MSLN and UPK3B were also detected in other cell types. MSLN was detected in bronchial epithelial cells and alveolar epithelial cells and UPK3B was detected in retinal pigment epithelial cells and urothelial cells. Testing the cell line panel, MSLN was detected in 15 of the 16 mesothelioma cells lines, whereas LRRN4 was only detected in 8 and UPK3B in 6. Interestingly MSLN levels appear to be upregulated in the mesothelioma lines compared to the primary mesothelial cells, while LRRN4 and UPK3B, are either lost or down-regulated. Despite the higher fraction of mesothelioma lines positive for MSLN, it was also detected at high levels in 2 lung cancer lines and 3 other unrelated cancer lines derived from papillotubular adenocarcinoma, signet ring carcinoma and transitional cell carcinoma.

[1]  A. Neuwirth,et al.  Mesothelial proteins are expressed in the human cornea. , 2010, Experimental eye research.

[2]  C. Soskolne,et al.  The Case for a Global Ban on Asbestos , 2010, Environmental health perspectives.

[3]  A. Hiraki,et al.  The first nationwide survival analysis of Japanese mesothelioma patients from Vital Statistics of Japan. , 2010 .

[4]  J. H. van Bockel,et al.  MIF Deficiency Reduces Chronic Inflammation in White Adipose Tissue and Impairs the Development of Insulin Resistance, Glucose Intolerance, and Associated Atherosclerotic Disease , 2009, Circulation research.

[5]  M. Chida,et al.  [Early malignant pleural mesothelioma; report of a case]. , 2009, Kyobu geka. The Japanese journal of thoracic surgery.

[6]  E. Meiri,et al.  MicroRNA-based assay for differential diagnosis of mesothelioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Maeda,et al.  Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin‐expressing cancers , 2009, Pathology international.

[8]  R. Lucito,et al.  Genomic events associated with progression of pleural malignant mesothelioma , 2009, International journal of cancer.

[9]  S. Skates,et al.  Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[11]  M. Maeda,et al.  Establishment of a novel specific ELISA system for rat N‐ and C‐ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma , 2008, Cancer science.

[12]  P. Paré,et al.  Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. , 2008, American journal of respiratory and critical care medicine.

[13]  Shenmin Zhang,et al.  HSP70 INHIBITS APOPTOSIS IN PANCREATIC CANCER CELLS BY TWO INDEPENDENT MECHANISMS: ATTENUATING CYTOSOLIC CA2+ AND STABILIZING LYSOSOMES , 2007 .

[14]  W. J. Allard,et al.  MESOMARK(®) in vitro diagnostic test for mesothelioma. , 2007, Expert opinion on medical diagnostics.

[15]  N. Sardesai,et al.  MESOMARK: a potential test for malignant pleural mesothelioma. , 2007, Clinical chemistry.

[16]  B. Simon,et al.  Microarray analysis of regional cellular responses to local mechanical stress in acute lung injury. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[17]  Jeremy J. W. Chen,et al.  Topology-based cancer classification and related pathway mining using microarray data , 2006, Nucleic acids research.

[18]  M. Kondo,et al.  Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients , 2006, Cancer science.

[19]  A. Olshen,et al.  Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. , 2006, Cancer research.

[20]  Amie Y Lee,et al.  Wnt2 as a new therapeutic target in malignant pleural mesothelioma , 2005, International journal of cancer.

[21]  K. Dahlman-Wright,et al.  Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling , 2005, The Journal of pathology.

[22]  Yoshihide Hayashizaki,et al.  Expression analysis of genes responsible for serotonin signaling in the brain , 2005, Neurobiology of Disease.

[23]  David J Sugarbaker,et al.  Tumorigenesis and Neoplastic Progression Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling , 2005 .

[24]  T. Manabe,et al.  Neuronal Leucine-Rich Repeat Protein 4 Functions in Hippocampus-Dependent Long-Lasting Memory , 2005, Molecular and Cellular Biology.

[25]  A. Bergeret,et al.  [Asbestos-related occupational cancers]. , 2004, La Revue du praticien.

[26]  Y. Hayashizaki,et al.  Identification of region‐specific transcription factor genes in the adult mouse brain by medium‐scale real‐time RT‐PCR , 2004, FEBS letters.

[27]  T. Speed,et al.  GOstat: find statistically overrepresented Gene Ontologies within a group of genes. , 2004, Bioinformatics.

[28]  K. Dobra,et al.  Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells. , 2004, Anticancer research.

[29]  N. Ordóñez,et al.  Application of Mesothelin Immunostaining in Tumor Diagnosis , 2003, The American journal of surgical pathology.

[30]  David Yang,et al.  Identification of cervical cancer markers by cDNA and tissue microarrays. , 2003, Cancer research.

[31]  S. Ramaswamy,et al.  Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. , 2002, Cancer research.

[32]  John David,et al.  Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K J O'Byrne,et al.  Chronic immune activation and inflammation as the cause of malignancy , 2001, British Journal of Cancer.

[34]  G. Leikauf,et al.  Differential gene expression in mesothelioma , 2000, FEBS letters.

[35]  Z. Ye,et al.  Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  N. Yamaguchi,et al.  Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*) , 1995, The Journal of Biological Chemistry.

[38]  E. Stylianou,et al.  Source of peritoneal proteoglycans. Human peritoneal mesothelial cells synthesize and secrete mainly small dermatan sulfate proteoglycans. , 1995, The American journal of pathology.

[39]  J. Morris,et al.  Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. , 1995, The American journal of pathology.

[40]  L. Weiss,et al.  Ber‐EP4 Antibody as a Discriminant in the Differential Diagnosis of Malignant Mesothelioma Versus Adenocarcinoma , 1991, The American journal of surgical pathology.

[41]  A. Musk,et al.  Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions , 1991, International journal of cancer.

[42]  T. H. van der Kwast,et al.  Characterization of three human malignant mesothelioma cell lines. , 1989, Cancer genetics and cytogenetics.

[43]  M. Hobbs,et al.  Epidemiology of malignant mesothelioma in Western Australia. , 1984, The Medical journal of Australia.

[44]  E. C. Hammond,et al.  Latency of asbestos disease among insulation workers in the United States and Canada , 1980, Cancer.

[45]  Mcnulty Jc.  Malignant pleural mesothelioma in an asbestos worker. , 1962 .

[46]  J. C. Mcnulty.  MALIGNANT PLEURAL MESOTHELIOMA IN AN ASBESTOS WORKER , 1962, The Medical journal of Australia.

[47]  J. Wagner,et al.  Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province , 1960, British journal of industrial medicine.

[48]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[49]  B. Jasani,et al.  The use of vimentin antibodies in the diagnosis of malignant mesothelioma , 2004, Virchows Archiv A.

[50]  J. Minna,et al.  NCI‐navy medical oncology branch cell line data base , 1996, Journal of cellular biochemistry. Supplement.

[51]  R. Doll,et al.  Mortality among asbestos workers. , 1966, Proceedings of the Royal Society of Medicine.